Carcinoma in-situ of the Breast

Top Rated5(1 reviews)

Carcinoma in-situ of the Breast is a Continuing Professional Development (CPD) course designed to provide healthcare professionals with an evidence-based understanding of non-invasive breast cancer conditions, including Ductal Carcinoma in Situ (DCIS) and Lobular Carcinoma in Situ (LCIS). The course explores the pathology, diagnosis, imaging, biopsy techniques, treatment pathways, patient counselling, and evolving management approaches for carcinoma in-situ of the breast. Breast carcinoma in-situ refers to abnormal cells confined within the ducts or lobules of the breast without invasion into surrounding breast tissue. While these conditions are considered non-invasive, early recognition and appropriate management are important to reduce progression risk and improve patient outcomes.

7 Modules1 hour
$169$0
Start Learning
Carcinoma in-situ of the Breast

Learning Outcomes

What you'll learn

  • Understand the difference between invasive breast cancer and carcinoma in-situ.
  • Differentiate between Ductal Carcinoma in Situ (DCIS) and Lobular Carcinoma in Situ (LCIS).
  • Recognise the pathology and biological behaviour of non-invasive breast lesions.
  • Outline the imaging investigations used in the diagnosis of breast carcinoma in-situ.
  • Understand biopsy techniques and pathology assessment processes.
  • Discuss treatment options including surveillance, surgery, radiation therapy, and endocrine management.
  • Identify patients who may require specialist referral and multidisciplinary care.
  • Recognise evolving approaches aimed at reducing overtreatment in selected patients.
  • Support patients through education, communication, and shared decision-making.
  • Apply evidence-based knowledge to breast cancer screening and clinical practice.

Stay updated with our

Healthcare trainingHealthcare training

Training Overview

  • Understanding Breast Carcinoma in-situ
  • DCIS and LCIS – Key Differences
  • Imaging and Diagnostic Assessment
  • Biopsy, Pathology, and Risk Assessment
  • Treatment Options and Patient Management
  • Avoiding Overtreatment and Future Directions
  • Summary
Healthcare trainingHealthcare trainingHealthcare trainingHealthcare trainingHealthcare trainingHealthcare trainingHealthcare training

Top reviews

FA

Faida

User fromcare-learning

5

simple but informative

Posted on 27/05/2026

You May Also Like

Take Your
Learning Anywhere

Stay on top of your learning with the Care Learning app.

Download on the App StoreGet it on Google Play

Are you a qualified
Trainer or Instructor?

Join Care Learning as a trainer and deliver high-quality courses to learners across healthcare and workplace training.

Refer a Friend &
Earn Rewards.

Invite healthcare professionals to join Care Learning and get rewarded when your referral successfully joins.

1 / 3

Frequently asked questions

It is a non-invasive breast condition where abnormal cells remain confined within the ducts or lobules.

DCIS occurs in the ducts and may progress to invasive cancer, while LCIS develops in the lobules and mainly indicates increased breast cancer risk.

How is carcinoma in-situ detected? It is commonly detected through breast screening mammography and confirmed with biopsy.

Mammography, ultrasound, and breast MRI may be used depending on clinical circumstances.

Selected low-risk patients may be suitable for surveillance under specialist supervision.

Multidisciplinary teams help ensure accurate diagnosis, treatment planning, and patient-centred care.